about
Understanding melanoma stem cellsSkin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.Converting biology into clinical benefit: lessons learned from BRAF inhibitors.Vitamin D as an adjuvant in melanoma therapy.Molecular pathology of cutaneous melanomaGastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic reviewManagement of the cutaneous adverse effects of antimelanoma therapyAnti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?Utility of ipilimumab in melanoma patients who progress on anti-PD-1 therapyWhat is new in melanoma after European Cancer Congress 2017?Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapyImmunotherapy in malignant melanoma: recent approaches and new perspectivesTalimogene laherparepvec: overview, combination therapy and current practicesAdjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapyEmerging immune therapy of metastatic melanoma in the older patient: does age really matter?Targeting immune checkpoints in melanoma: an updateImmune checkpoint inhibitors in melanomaIpilimumab for the treatment of melanomaCombination approaches and anti-PD1 therapies: the focus of new research at ESMO and SMRCombination therapies in advanced melanomaSubcutaneous metastases from melanoma: a discussion of clinical experienceWhere to start with systemic melanoma therapy?Has the melanoma information tsunami become a maelstrom?Making sense of the melanoma information tsunamiBowel perforation associated with robust response to BRAF/MEK inhibitor therapy for -mutant melanoma: a case reportThe role of chemotherapy in the modern management of melanomaCDK4 inhibitors an emerging strategy for the treatment of melanomaPredicting melanoma risk: theory, practice and future challengesInterferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experienceCombatting mucosal melanoma: recent advances and future perspectivesCheckpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populationsImproving the diagnosis and treatment of acral melanocytic lesionsTowards skin cancer prevention and early detection: evolution of skin cancer awareness campaigns in AustraliaThe impact of socioeconomic status on melanoma clinical trial participation: an observational cohort study from AustraliaIntralesional treatment for advanced melanoma: what's on the horizon?En1 fibroblasts and melanoma.Journal Watch: our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of melanoma management.Neoadjuvant treatment for melanoma: current challenges and future perspectives.Immunohistochemistry for an improved clinical workflow in the era of personalized melanoma therapy?Melanoma vaccines and viral-based immunotherapies: a special focus issue from Melanoma Management.
P1433
Q36292299-C437BE31-A031-45A7-A4C3-92E1F7C679B2Q38652548-1F345580-6426-424C-8A7F-C069FBEC2976Q38940098-710B89FB-1A74-4E06-BAAA-0BAC0BF7FFDFQ41548479-633A3132-4EC2-45FA-AD35-2FED8F2AADCBQ56428911-32A606D3-FC91-4AD1-BA27-F2F298F585BDQ56893081-EBFE01A0-F374-4616-9D0D-AB7EDB2E5AD7Q56893430-EAF9917C-6963-4952-B2B6-D8427DD10BA0Q56893675-491B47FE-2F75-40AD-94B7-8C5D589B8D05Q56893686-5C66A870-7D8A-4979-BF9B-E7E39C2B1D3BQ56894089-595849F4-C494-4E44-87C6-787FA2CF73A3Q56894275-1702B739-72E7-4085-9374-01D7F11FA030Q56894289-B1D59738-9B51-4E94-9F2F-BFCB435FF71EQ56894524-94F75C10-44FE-441E-B8CE-628207858991Q56895044-D2523551-94CD-4CDC-9FC8-CEF5B7385DEEQ56895279-C16B3F02-5BFD-4557-9812-2BC73DF45168Q56895678-D3CCBCCE-4CD7-4CBA-9A17-A96ECB272054Q56895914-B777F964-E401-4146-B144-77B57D123782Q56896291-C850396A-C58D-4202-86D3-E87FE6BFA5C0Q56896300-95AEA960-4980-41A4-8279-B780D7DA002AQ56896764-E27D1118-A816-439A-B2E1-E1E36AC3EF06Q56896770-EE7F391A-2012-4E33-BC9F-FD6009A258C6Q56896779-EED04CC5-979D-4A98-9901-BEE2DCC252D5Q57095063-E9B0E6DE-4201-44DA-AF22-3F552102364EQ57100732-F7E28330-C979-4613-B6CA-869EB5E05EBCQ57107446-A3D2FE53-99C4-426E-A27A-524C7515C6F4Q57569574-E938C5A8-2E7C-4889-AA45-604F43B39DDEQ57571832-254CEBC4-0A6C-4782-B317-CAC2D4F363F4Q57742458-D5377A49-EB9D-4ACB-BFE3-09584E782A9AQ58747512-F41AF582-D9A8-46CD-9945-1BF62F567522Q59126427-9B6EDC77-DC63-4379-B5DE-940E6BEA91D0Q59135661-3EB17873-BC77-4824-A2F0-844FFB87DEDBQ59228527-0C0E6520-5003-4CE5-BBA5-B81FE242B276Q59655700-CFA0FAF0-2ED7-40F7-88C7-3FC507968483Q61387631-23531378-5C6A-48B0-9F66-1EB218C1BF66Q64883850-48F3FAC2-C3C2-4A40-8B76-7DE12D1A01E8Q64889906-16EF2258-EE00-4DCC-888F-DFA70EFB685EQ64890365-75B4C77F-876E-4233-BEBD-8B55B572AF84Q64892269-9543E621-78DC-4468-AE08-E7D7BEC14DA5Q64913578-537FC75C-B7C7-46DB-B479-DD418E80A6C4Q64915604-9E305BD8-CC74-4A80-BD3F-59F46679B940
P1433
description
journal
@en
revista científica
@es
wetenschappelijk tijdschrift
@nl
wissenschaftliche Fachzeitschrift
@de
name
Melanoma management
@ast
Melanoma management
@en
Melanoma management
@es
Melanoma management
@nl
type
label
Melanoma management
@ast
Melanoma management
@en
Melanoma management
@es
Melanoma management
@nl
altLabel
Melanoma Manag
@en
Melanoma Management
@en
prefLabel
Melanoma management
@ast
Melanoma management
@en
Melanoma management
@es
Melanoma management
@nl
P31
P3181
P1055
P1156
21100463101
P1476
Melanoma management
@en